Maria Podolak‐Dawidziak

Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study

Steven W. Pipe, Midori Shima, Michaela Lehle et al. · The Lancet Haematology · 2019 · 373 citations · Full text

Haven 4, Hematology, Non-randomised Phase 3 +2

Altered plasma fibrin clot properties and fibrinolysis in patients with multiple myeloma

Anetta Undas, Lidia Usnarska‐Zubkiewicz, Grzegorz Helbig et al. · European Journal of Clinical Investigation · 2014 · 25 citations · Full text

Induction therapy alters plasma fibrin clot properties in multiple myeloma patients

Anetta Undas, Lidia Usnarska‐Zubkiewicz, Grzegorz Helbig et al. · Blood Coagulation & Fibrinolysis · 2015 · 23 citations · Full text

Thrombopoiesis, Thrombosis, Hematological Malignancy +14

Serum thrombopoietin levels in patients with reactive thrombocytosis due to lung cancer and in patients with essential thrombocythemia.

B Weryńska, Rodryg Ramlau, Maria Podolak‐Dawidziak et al. · PubMed · 2003 · 20 citations

Immunology, Pathology, Immunotherapy +19

Registry of inherited bleeding disorders in Poland – current status and potential role of the HemoRec database

Joanna Zdziarska, Krzysztof Chojnowski, Anna Klukowska et al. · Haemophilia · 2010 · 15 citations